STK38 overexpression significantly promoted tumor growth, as expected, while GlaB treatment markedly suppressed tumor progression, with the most substantial reduction observed in the STK38-overexpressing group treated with GlaB (Fig. 6b–d). This evidence concerns the gene STK38 and neoplasm.